Lactobacillus paracasei strain
US-12152232-B2 · Nov 26, 2024 · US
US11946036B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11946036-B2 |
| Application number | US-202217671001-A |
| Country | US |
| Kind code | B2 |
| Filing date | Feb 14, 2022 |
| Priority date | Jul 15, 2016 |
| Publication date | Apr 2, 2024 |
| Grant date | Apr 2, 2024 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
The present invention discloses a bacterium and an obtaining method and application thereof. The bacterium has a property of coproducing 1,3-propanediol and D-lactic acid. Further, the bacterium is Klebsiella oxytoca , including Klebsiella oxytoca PDL-5 CCTCC M 2016185. The obtaining method of the bacterium may be to obtain the bacterium by directly screening wild bacteria that satisfy conditions from the environment or performing gene engineering modification to wild bacteria. The present invention has the advantages that the bacteria can coproduce 1,3-propanediol and D-lactic acid through fermentation, the molar conversion rate and the concentration of the two products are very high, the types of byproducts are few, the concentration is low, the product extraction process is simplified, the high-efficiency biological production of 1,3-propanediol and D-lactic acid can be realized, and the industrial application prospect is very great.
Opening claim text (preview).
The invention claimed is: 1. An artificial bacterium, wherein the artificial bacterium is Klebsiella oxytoca PDL-0 with genes budA and budB defects, or the artificial bacterium is Klebsiella oxytoca PDL-0 with genes budA, budB and adhE defects; or the artificial bacterium is Klebsiella oxytoca PDL-0 with genes budA, budB, adhE and ackA-pta defects; or the artificial bacterium is Klebsiella oxytoca PDL-0 with genes budA, budB, adhE, ackA-pta and poxB defects; or the artificial bacterium is Klebsiella oxytoca PDL-0 with genes budA, budB, adhE, ackA-pta, poxB and frdA defects, and wherein the Klebsiella oxytoca PDL-0 was collected in China Center for Type Culture Collection on Apr. 8, 2016, and the collection registration number is CCTCC M 2016184. 2. The artificial bacterium according to claim 1 , wherein a DNA sequence of the budA is shown in SEQ ID NO:1; and/or a DNA sequence of the budB is shown in SEQ ID NO:2; and/or a DNA sequence of the adhE is shown in SEQ ID NO:3; and/or a DNA sequence of the ackA-pta is shown in SEQ ID NO:4; and/or a DNA sequence of the poxB is shown in SEQ ID NO:5; and/or a DNA sequence of the frdA is shown in SEQ ID NO:6. 3. The artificial bacterium according to claim 1 , wherein the artificial bacterium has a property of coproducing 1,3-propanediol and D-lactic acid and in products obtained through coproduction, a total conversion rate of 1,3-propanediol and D-lactic acid exceeds 90%. 4. The artificial bacterium according to claim 1 , wherein the artificial bacterium has the following metabolic pathways: 1) glycerol→1,3-propanediol; and 2) glycerol→pyruvic acid→D-lactic acid.
Bacteria; Culture media therefor · CPC title
acting on CH-OH groups as donors (1.1) · CPC title
acting on the aldehyde or oxo group of donors (1.2) · CPC title
acting on the CH-CH group of donors (1.3) · CPC title
transferring aldehyde or ketonic groups (2.2) · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.